Flow cytometry and receptor occupancy in immune-oncology
| Autor: | Alessandra Audia, Rachel Bunting, Gregory Bannish, Chelsea Riveley |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Drug media_common.quotation_subject Receptor expression Clinical Biochemistry Computational biology Epitope Antibodies Flow cytometry 03 medical and health sciences 0302 clinical medicine Immune system Drug Discovery medicine Humans Receptor media_common Pharmacology medicine.diagnostic_test biology Flow Cytometry 030104 developmental biology Targeted drug delivery 030220 oncology & carcinogenesis biology.protein Antibody |
| Zdroj: | Expert opinion on biological therapy. 22(1) |
| ISSN: | 1744-7682 |
| Popis: | Introduction: Immunotherapies are focused on strategies that alter immune responses, using antibodies that binds to receptors on different immune cell subsets and either activate or suppress their functions depending on the immune response being targeted. Hence, the necessity of developing assays that assess the functional and biological effect of a therapeutic on its target. When incorporated into high-parameter flow cytometry panels, receptor occupancy assay can simultaneously evaluate receptor expression and drug occupancy on defined cell subsets, which can provide information related to functional effects, and safety.Areas covered: This review focuses on the importance of developing, optimizing, and validating a robust Receptor Occupancy Assay (ROA) to improve dose selection, pharmacology monitoring and safety mainly in clinical settings.Expert opinion: The designing of an ROA can be challenging and can lead to exaggerated pharmacology if not accurately developed, optimized, and validated. However, improvements in our understanding of epitopes, binding, affinities, and pharmacological effects may lead to improved antibody drug targeting and receptor evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|